Dynavax Technologies Corp.

As of October 10, 2025, Dynavax Technologies Corp. is in a bearish trend, indicated by negative MACD readings and underperformance of 22% year-to-date compared to the S&P 500's 11.41% gain.

As of October 10, 2025, Dynavax Technologies Corp. is in a bearish trend with weak strength indicators, underperforming the S&P 500 by 22% year-to-date and 10% over the last three years.

As of September 4, 2025, Dynavax Technologies Corp. is in a bearish trend with weak momentum indicators, underperforming the S&P 500 with year-to-date and one-year returns of -23.65% and -13.02%, respectively.

As of May 6, 2025, Dynavax Technologies Corp. is considered risky due to its high P/E ratio of 54, negative EV to EBITDA ratio of -832.88, and poor stock performance, indicating it may be overvalued compared to its peers and the broader market.

As of May 6, 2025, Dynavax Technologies Corp. is considered overvalued and risky, with a high P/E ratio of 54 and poor profitability metrics, leading to a year-to-date stock performance of -23.49%, significantly underperforming the S&P 500.

As of June 11, 2025, Dynavax Technologies Corp. is in a strong bearish trend, indicated by multiple technical indicators such as MACD, Bollinger Bands, and moving averages across both weekly and monthly time frames.

As of March 2022, the management team of Dynavax Technologies Corp. includes Dr. Andrew Hack (Interim Independent Chairman), Ryan Spencer (CEO), and directors Julie Eastland, Brent MacGregor, Peter Paradiso, Francis Cano, and Daniel Kisner. They oversee the company's strategic direction and operations.

Dynavax Technologies Corp. is a clinical-stage immunotherapy company that focuses on stimulating immune responses through toll-like receptor activation. As of March 2025, it reported net sales of $68 million and a net loss of $96 million, with a market cap of approximately $1.2 billion.

As of Jun 18, Dynavax Technologies Corp. has a market capitalization of 1,199.61 million and reported net sales of 294.62 million with a net profit of -60.07 million over the latest four quarters. Shareholder's funds are 596.80 million, and total assets amount to 986.26 million.